News

The sale buoyed hopes that Glaxo would restart a share buyback programme to bolster its share price, and also freed cash for Glaxo to pay a £2.2bn net

Net sales decreased 6% to $992m in the fourth quarter of 2010. Specialty Injectable Pharmaceuticals sales were stable despite the year-over-year impact of the temporary discontinuation of US

The study will evaluate several dose strengths of VIBEX MTX which is being developed for the treatment of rheumatoid arthritis. VIBEX MTX is Antares’ proprietary – wholly owned

Rabeprazole sodium extended-release capsules, 50 mg, is an investigational proton pump inhibitor, which is under review for the healing and long-term maintenance of healing and symptom resolution of

The pharmaceutical sector is facing an unprecedented period of patent expiries when mega-blockbusters including Pfizer’s Lipitor, Bristol-Myers Squibb‘s Plavix and Eli Lilly’s Zyprexa will be exposed to cheap,

The studies achieved a median set-up time of 54 days compared with an average of 140 days for all commercial studies in the NHS Research’s database of active

The samples will be shipped for the approval of the US FDA before it can introduce the products. Glenmark has invested about $20m in the plant that has

The Data Monitoring Committee decided to stop enrollment following an independent recommendation that no new or recently enrolled patients continue treatment in the trial because of safety concerns

Trabedersen is a first-in-class gene silencing antisense compound designed to inhibit the tumour factor – transforming growth factor beta 2 (TGF-ß2) at its translational level. The efficacy and